Savant Capital
RNTX icon

Savant Capital’s Rein Therapeutics RNTX Stock Holding History

Savant Capital’s Portfolio RNTX Stock Details RNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$49.1K Buy
61,056
+30,528
+100% +$25K ﹤0.01% 2386
2026
Q2 		$23.3K Buy
+30,528
New +$36.9K ﹤0.01% 1836

Other funds holding RNTX

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
University of Texas/Texas AM Investment Management Co (UTIMCO)
University of Texas/Texas AM Investment Management Co (UTIMCO) Austin, Texas $798M AUM 22.92% 1-Year Est. Return
Texas Capital Bank Wealth Management Services
Texas Capital Bank Wealth Management Services Dallas, Texas $1.94B AUM 19.18% 1-Year Est. Return
Sigma Planning Corp
Sigma Planning Corp Ann Arbor, Michigan $3.88B AUM 23.38% 1-Year Est. Return
Gagnon Securities
Gagnon Securities New York $577M AUM 61.61% 1-Year Est. Return
Rock Creek Group
Rock Creek Group Washington, District of Columbia $1.04B AUM 6.61% 1-Year Est. Return
WAM
Warberg Asset Management Winnetka, Illinois $755M AUM 21.42% 1-Year Est. Return
Rossby Financial
Rossby Financial Melbourne, Florida $673M AUM 21.47% 1-Year Est. Return
Americana Partners
Americana Partners Houston, Texas $4.67B AUM 26.97% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Savant Capital's RNTX Position: Q3 2026 in Review

Savant Capital increased its Rein Therapeutics (RNTX) stake by 100% in Q3 2026, buying an estimated $25K and bringing the position to 61,056 shares worth $49.1K. The position accounts for ﹤0.01% of the portfolio, ranked #2386.

Savant Capital first reported a position in RNTX in Q2 2026 and has held it in 2 quarters since. 27 funds tracked by Wall St. Rank hold RNTX as of Q3 2026.

  • Savant Capital held 61,056 shares of Rein Therapeutics worth $49.1K as of Q3 2026.
  • Savant Capital bought 30,528 Rein Therapeutics shares in Q3 2026, an estimated $25K.
  • Rein Therapeutics made up ﹤0.01% of Savant Capital's portfolio in Q3 2026, its #2386 holding.
  • Savant Capital first reported a position in Rein Therapeutics in Q2 2026 and has held it in 2 quarters since.
  • 27 funds tracked by Wall St. Rank held Rein Therapeutics as of Q3 2026.

Based on Savant Capital's 13F filing for Q3 2026, filed 6 Nov 2026.